Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
Status:
Withdrawn
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if Prostaphane is effective and can help reduce the
progression of bladder cancer. Researchers also want to find out if Prostaphane is safe and
tolerable, and to evaluate how Prostaphane works to reduce the progression of bladder cancer.
This study will compare Prostaphane with a placebo to see if taking Prostaphane is better
than taking a placebo. A placebo is a pill that looks like Prostaphane but has no drug or
other active ingredients in it.
The study will be presented to eligible patients by the patient's surgeon at the time when an
appointment is made for cystoscopy for suspicion of bladder cancer (BC) or to confirm BC
diagnosis.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Johns Hopkins University National Institutes of Health (NIH)